DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-3.3%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$2.58B
AUM Growth
+$2.58B
(+20%)
Cap. Flow
+$513M
Cap. Flow
% of AUM
19.91%
Top 10 Holdings %
Top 10 Hldgs %
46.08%
Holding
70
New
15
Increased
18
Reduced
13
Closed
6
Top Buys
| 1 |
Guardant Health
GH
|
$75.6M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$54.8M |
| 3 |
Axsome Therapeutics
AXSM
|
$52.9M |
| 4 |
Apogee Therapeutics
APGE
|
$51.4M |
| 5 |
NovoCure
NVCR
|
$40.4M |
Top Sells
| 1 |
Immunovant
IMVT
|
$101M |
| 2 |
Structure Therapeutics
GPCR
|
$36.9M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$14.5M |
| 4 |
Insmed
INSM
|
$12.6M |
| 5 |
INZY
Inozyme Pharma
INZY
|
$9.16M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
4D Molecular Therapeutics
FDMT
$287M
| $35.4M | 1.37% |
2,778,107
| – | – |
|
|
AUTL
27
Autolus Therapeutics
AUTL
$383M
| $35M | 1.35% |
15,000,000
| – | – |
|
28
Neurocrine Biosciences
NBIX
$13.5B
| $33.8M | 1.3% |
+300,000
| New | +$33.8M |
|
29
Terns Pharmaceuticals
TERN
$651M
| $30.2M | 1.16% |
6,000,000
+4,900,808
| +446% | +$24.7M |
|
30
RAPT Therapeutics
RAPT
$187M
| $24.9M | 0.96% |
187,500
+61,930
| +49% | +$8.23M |
|
31
Beam Therapeutics
BEAM
$1.9B
| $24.4M | 0.94% |
1,015,641
-301,675
| -23% | -$7.26M |
|
32
AnaptysBio
ANAB
$630M
| $24.2M | 0.93% |
+1,345,813
| New | +$24.2M |
|
33
Olema Pharmaceuticals
OLMA
$432M
| $23.8M | 0.92% |
+1,930,894
| New | +$23.8M |
|
34
Nurix Therapeutics
NRIX
$723M
| $23.6M | 0.91% |
2,997,830
| – | – |
|
35
ANI Pharmaceuticals
ANIP
$2.06B
| $23.2M | 0.9% |
400,000
-114,021
| -22% | -$6.62M |
|
36
Amylyx Pharmaceuticals
AMLX
$877M
| $23.1M | 0.89% |
+1,259,335
| New | +$23.1M |
|
37
BioNTech
BNTX
$24.1B
| $21.7M | 0.84% |
+200,000
| New | +$21.7M |
|
38
Dyne Therapeutics
DYN
$1.92B
| $21.5M | 0.83% |
2,403,672
-96,240
| -4% | -$862K |
|
39
Moderna
MRNA
$9.36B
| $20.7M | 0.8% |
+200,000
| New | +$20.7M |
|
|
SLN
40
Silence Therapeutics
SLN
$237M
| $19.2M | 0.74% |
1,951,580
| – | – |
|
|
PNT
41
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $18.6M | 0.72% |
2,781,565
| – | – |
|
42
Zura Bio
ZURA
$132M
| $16.7M | 0.64% |
2,523,000
| – | – |
|
|
ORTX
43
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $15.8M | 0.61% |
2,041,670
| – | – |
|
44
Edgewise Therapeutics
EWTX
$1.54B
| $15.8M | 0.61% |
2,750,000
| – | – |
|
45
Nektar Therapeutics
NKTR
$543M
| $11M | 0.42% |
1,226,667
+28,436
| +2% | +$254K |
|
|
MORF
46
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $10.8M | 0.42% |
470,647
+253,895
| +117% | +$5.82M |
|
47
Agios Pharmaceuticals
AGIO
$2.36B
| $10.5M | 0.4% |
+422,247
| New | +$10.5M |
|
48
Acumen Pharmaceuticals
ABOS
$82.4M
| $10.4M | 0.4% |
2,513,044
-1,403,317
| -36% | -$5.82M |
|
49
Nuvation Bio
NUVB
$1.08B
| $10.3M | 0.4% |
7,720,688
| – | – |
|
|
VIGL
50
DELISTED
Vigil Neuroscience
VIGL
| $9.52M | 0.37% |
1,767,131
-6,278
| -0.4% | -$33.8K |
|